Want a downturn in European markets? In your inbox before opening, every day. Sign up here.
AstraZeneca plc said it would buy Alexian added 39 39 billion in cash and shares to Alexian Pharmaceuticals Inc., an expert in the development of treatments for rare diseases and immunology.
The offer gives Alexian 17 175 per share, a 45% premium to the closing price on Friday.
Acquiring Alexian will increase AstraZeneca in areas such as the treatment of blood disorders, building such as the replacement of Chief Executive Officer Pascal Soriot. Since taking office in 2012, he has pushed the UK drugmaker into other lucrative areas, such as cancer treatment.
AstraZeneca, with Oxford University has also developed a Covid-19 vaccine that has shown efficacy in large trials, despite questions surrounding the study’s results.
Alexian shareholders will receive $ 60 cash for each Alexian share and 2.1243 AstraZeneca American Depository shares, AstraZeneca said in a press release. Saturday.
For a market value of 7 107 billion ($ 142 billion), AstraZeneca’s stock has risen 7% this year and nearly 70% this year.
The acquisition is expected to close in the third quarter of 2021 and Alexian shareholders own 15% in the joint venture.
.
